Modality
Gene Editing
MOA
PD-L1i
Target
AuroraA
Pathway
T-cell
Ovarian CaParkinson'sPNH
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
Nov 2020
→ Oct 2027
Phase 2Current
NCT05228209
2,476 pts·Parkinson's
2020-11→2027-10·Terminated
2,476 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-211.6y awayPh2 Data· Parkinson's
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2027-10-21 · 1.6y away
Parkinson's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05228209 | Phase 2 | Parkinson's | Terminated | 2476 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |